MDXXF (Pharmala Biotech Holdings) Tariff Resilience Score: 5/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.11
GF Value $0.15
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Tariff Resilience Score?

Pharmala Biotech Holdings MDXXF +0.44% 33 Tariff Resilience Score is 5 as of Jul. 20, 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.15 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, Pharmala Biotech Holdings ranks better than 62.41% on this metric.

Pharmala Biotech Holdings has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Pharmala Biotech Holdings has Pharmala Biotech is moderately vulnerable due to its global supply chain for pharmaceutical ingredients. The company has limited pricing power and relies on exports, but it can switch suppliers if needed. Industry-specific exemptions are limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pharmala Biotech Holdings might have Average Resilient.

Pharmala Biotech Holdings  (OTCPK:MDXXF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pharmala Biotech Holdings Tariff Resilience Score Related Terms

MDXXF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Tariff Resilience Score falls into.


MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Pharmala Biotech Holdings (MDXXF) has a Tariff Resilience Score of 5 as of Jul. 20, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pharmala Biotech Holdings ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Pharmala Biotech Holdings' Tariff Resilience Score too high?
Pharmala Biotech Holdings' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Pharmala Biotech Holdings' value of 5 is 25% above this industry median. Based on the distribution chart, Pharmala Biotech Holdings ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmala Biotech Holdings ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Pharmala Biotech Holdings in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Pharmala Biotech Holdings' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmala Biotech Holdings's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmala Biotech Holdings's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 29.2% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Tariff Resilience Score is 5 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 29.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Significantly Undervalued.

Key valuation signals for MDXXF:

  • Tariff Resilience Score: 5
  • GF Value™: $0.15 vs. price of $0.11 (29.2% below fair value)
  • GF Score™: 33/100 with 2 warning signs
  • Industry Position: 25% above the Biotechnology median (#515 of 1370)

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value